Iradimed (IRMD) Equity Average (2014 - 2026)

Iradimed (IRMD) has 13 years of Equity Average data on file, last reported at $96.6 million in Q1 2026.

• Equity Average for Q1 2026 came in at $96.6 million, up 9.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.6 million (up 9.19% YoY), and the FY2025 annual result was $90.7 million, up 14.66% from the prior year.
• Equity Average steadied at $96.6 million in Q1 2026 per IRMD's latest filing, from $96.5 million in the prior quarter.
• Over five years, Equity Average peaked at $96.6 million in Q1 2026 and troughed at $64.2 million in Q2 2022.
• A 5-year average of $78.8 million and a median of $73.8 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average advanced 0.36% in 2022, then gained 19.88% in 2025.
• A 5-year view of Equity Average shows it stood at $71.7 million in 2022, then advanced by 1.77% to $73.0 million in 2023, then advanced by 16.62% to $85.1 million in 2024, then grew by 13.34% to $96.5 million in 2025, then gained by 0.08% to $96.6 million in 2026.
• Business Quant data shows IRMD's Equity Average at $96.6 million in Q1 2026, $96.5 million in Q4 2025, and $96.3 million in Q3 2025.